Daniel Nils Gotthardt, Jonas Senft, Peter Sauer, Karl Heinz Weiss, Christa Flechtenmacher, Isabella Eckerle, Yvonne Schaefer, Peter Schirmacher, Wolfgang Stremmel, Peter Schemmer, Paul Schnitzler – 25 July 2013 – Cholestatic complications, important causes of morbidity and mortality after orthotopic liver transplantation (OLT), often have an unclear etiology. Human cytomegalovirus (CMV) infections occur in immunosuppressed patients and can be detected in blood samples. However, CMV analyses of body fluids and biopsies are more sensitive.

Toru Ikegami, Huanlin Wang, Daisuke Imai, Yuki Bekki, Tomoharu Yoshizumi, Yo‐Ichi Yamashita, Takeo Toshima, Yuji Soejima, Ken Shirabe, Yoshihiko Maehara – 25 July 2013 – Although the round ligament, including the umbilical vein, could be used as a venous graft in living donor liver transplantation (LDLT), no studies have determined its appropriate use on the basis of pathological findings. We prospectively examined 19 LDLT cases in which the donor's round ligament was procured and used as a venous graft.

Quirino Lai, Alfonso W. Avolio, Ivo Graziadei, Gerd Otto, Massimo Rossi, Giuseppe Tisone, Pierre Goffette, Wolfgang Vogel, Michael B. Pitton, Jan Lerut, on behalf of the European Hepatocellular Cancer Liver Transplant Study Group – 19 July 2013 – Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre‐LT LRT are lacking.

Margaret Hellard, Joseph S. Doyle, Rachel Sacks‐Davis, Alexander J. Thompson, Emma McBryde – 19 July 2013

Rajeev Sharma, John Crowley, Robert Squires, Geoffrey Bond, Rakesh Sindhi, George Mazariegos, Kyle Soltys – 19 July 2013

Rodrigo Liberal, Yoh Zen, Giorgina Mieli‐Vergani, Diego Vergani – 19 July 2013 – Liver transplantation (LT) is an effective treatment for patients with end‐stage autoimmune liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Indications for LT for these diseases do not differ substantially from those used for other acute or chronic liver diseases. Despite the good outcomes reported, the recurrence of autoimmune liver disease is relatively common in the allograft.

Jonathan A. Fallowfield, Annette L. Hayden, Victoria K. Snowdon, Rebecca L. Aucott, Ben M. Stutchfield, Damian J. Mole, Antonella Pellicoro, Timothy T. Gordon‐Walker, Alexander Henke, Joerg Schrader, Palak J. Trivedi, Marc Princivalle, Stuart J. Forbes, Jane E. Collins, John P. Iredale – 19 July 2013 – Active myofibroblast (MF) contraction contributes significantly to the increased intrahepatic vascular resistance that is the primary cause of portal hypertension (PHT) in cirrhosis.

Brian L. Pearlman, Carole Ehleben – 19 July 2013 – The new standard of care for treatment‐naïve patients with hepatitis C virus (HCV) genotype 1 includes triple therapy with peginterferon, ribavirin, and a protease inhibitor. However, patients who achieve a rapid virologic response after 4 weeks of peginterferon and ribavirin therapy are likely to achieve a sustained virologic response (SVR), and we hypothesized that protease inhibitor therapy may be unnecessary in these patients.

Alexandru I. Musat, Courtney M. Pigott, Thomas M. Ellis, Rashmi M. Agni, Glen E. Leverson, Amy J. Powell, Katelyn R. Richards, Anthony M. D'Alessandro, Michael R. Lucey – 19 July 2013 – The significance of preexisting donor‐specific HLA antibodies (HLA‐DSAs) for liver allograft function is unclear. Our previous studies have shown that humoral alloreactivity frequently accompanies acute cellular rejection (ACR).

Behnam Saberi, Maria D. Ybanez, Heather S. Johnson, William A. Gaarde, Derick Han, Neil Kaplowitz – 19 July 2013 – This study examines the role of protein kinase C (PKC) and AMP‐activated kinase (AMPK) in acetaminophen (APAP) hepatotoxicity. Treatment of primary mouse hepatocytes with broad‐spectrum PKC inhibitors (Ro‐31‐8245, Go6983), protected against APAP cytotoxicity despite sustained c‐jun‐N‐terminal kinase (JNK) activation. Broad‐spectrum PKC inhibitor treatment enhanced p‐AMPK levels and AMPK regulated survival‐energy pathways including autophagy.